Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 9044.074 | 0.0047 | -0.9994 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 9044.074 | 0.0047 | -0.9994 | 0.6607 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14799.203 | 0.9735 | 0.9437 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14799.203 | 0.9735 | 0.9437 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14799.203 | 0.9356 | 0.8634 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14799.203 | 0.9356 | 0.8634 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14799.203 | 0.5319 | 0.0218 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14799.203 | 0.5319 | 0.0218 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14799.203 | 0.1171 | -0.7957 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14799.203 | 0.1171 | -0.7957 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14799.203 | 0.0436 | -0.9285 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14799.203 | 0.0436 | -0.9285 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14799.203 | 0.0188 | -0.9708 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14799.203 | 0.0188 | -0.9708 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14799.203 | 0.0120 | -0.9819 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14799.203 | 0.0120 | -0.9819 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14799.203 | 0.0115 | -0.9827 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14799.203 | 0.0115 | -0.9827 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14799.203 | 0.0063 | -0.9908 | 0.9401 | |
| SUM1315MO2 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14799.203 | 0.0063 | -0.9908 | 0.9401 | |
| SUM149PT | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7530.074 | 0.9581 | 0.9596 | 2.0964 | |
| SUM149PT | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7530.074 | 0.9581 | 0.9596 | 2.0964 | |
| SUM149PT | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7530.074 | 0.9721 | 0.9732 | 2.0964 | |
| SUM149PT | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7530.074 | 0.9721 | 0.9732 | 2.0964 | |
| SUM149PT | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7530.074 | 0.9575 | 0.9590 | 2.0964 |